News & Opinion
This report apparently focuses on financial conflict of interests, especially where there is a potential for patient harm.
An editorial in American Journal of Health-System Pharmacy describes the outcome of a legal action against their journal from a manufacturer who claimed that an article (abstract only, full text requires a subscription) published in the 15 March 2007 issue of AJHP defamed the manufacturer "through the criticism and test results published in the article" as the manufacturer's prod
The full piece, published on March 26th, which describes the operation as being a "congressional sting operation" is here, excerpt:
"The sting, detailed at a House Energy and Commerce Committee hearing Thursday, involved the creation of a fictitious company and a fake medical device, a surgical adhesive gel. The sham firm then applied to three for-profit oversight groups — called institutional review boards, or IRBs — for approval to begin a clinical trial using their adhesive on human subjects."
An editorial in JAMA1 describes a case of an author’s undeclared conflict of interest which was reported to the journal by a reader, Jonathan Leo. The reason for the editorial (in addition to a published correction) is that Leo sent a copy of his letter to the New York Times and also posted his concerns in a BMJ Rapid Response2 which appeared before JAMA published its correction in its print issue of March 11.
This month's Editorial (DOI: 10.1371/journal.pmed.1000038) in PLoS Medicine discusses how the publication of scientific research can be inappropriately influenced by various forms of bias and the effects of competing interests.
A report (free to view but registration required) in The Scientist describes the introduction by two US Senators of an amendment to the Economic Stimulus bill currently being debated in Congress which is apparently intended to better protect federally-funded NIH (National Institutes of Health) biomedical research from potential bias.